Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599871 | 0.84 | NOTUM (0.55) | NOTUMDRD2DRD4HTR2CHTR2A | |
| SCHEMBL1877071 | 0.84 | NOTUM (0.55) | NOTUMDRD2DRD4HTR2CHTR2A | |
| Indoline SCHEMBL22344753 | 0.81 | F7 (0.49) | DRD2DRD4HTR2CHTR2AHTR2B | |
| Indoline SCHEMBL5629 | 0.78 | — | — | |
| Indoline SCHEMBL29360339 | 0.78 | — | — | |
| Indoline SCHEMBL23295083 | 0.76 | HTR2C (0.50) | DRD2DRD4HTR2CGAAPNMT | |
| Indoline SCHEMBL3905169 | 0.76 | HTR2C (0.50) | DRD2DRD4HTR2CGAAPNMT | |
| Indoline SCHEMBL8297156 | 0.76 | HTR2C (0.50) | DRD2DRD4HTR2CGAAPNMT | |
| Indoline SCHEMBL11072860 | 0.76 | HTR2C (0.50) | DRD2DRD4HTR2CGAAPNMT | |
| Indoline SCHEMBL8297160 | 0.76 | HTR2C (0.50) | DRD2DRD4HTR2CGAAPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | CERVELLO THERAPEUTICS, LLC. | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | NOTUM 2655/4885DRD2 3508/4885DRD4 3772/4885 |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | NOTUM 2655/4885DRD2 3508/4885DRD4 3772/4885 |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | ROCK1, ROCK2, RHOA | NOTUM 2653/4885DRD2 4722/4885DRD4 4795/4885 |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | ROCK1, ROCK2, CIT | NOTUM 2655/4885DRD2 3508/4885DRD4 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.